9 recruiting, 4 completed, 1 active not recruiting, 1 unknown. 15 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Recruiting 9, Completed 4, Active not recruiting 1, Unknown 1 |
| Phase 1 | 6 | Recruiting 4, Completed 2 |
Follow ER+ Breast Cancer: new trials by email Literature Review of ER+ Breast Cancer trials Research Report on ER+ Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer Neoadjuvant endocrine therapy - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 176 | 2026-03-13 | 2026-06-04 |
| Circulating Tumor DNA Elacestrant - ER+ Breast Cancer | Phase 2 | Recruiting | Yale University | 50 | 2025-09-30 | 2026-09-21 |
| A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet - Metastatic Breast Cancer, Breast Cancer Stage I | Phase 1 / Phase 2 | Recruiting | Forward Pharmaceuticals Co., Ltd. | 196 | 2025-06-01 | 2026-01-07 |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. RYZ101, Standard of Care Endocrine Therapy - Metastatic Breast Cancer, HER2-negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | RayzeBio, Inc. | 64 | 2024-07-19 | 2026-10-06 |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies ETX-19477 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Recruiting | 858 Therapeutics, Inc. | 120 | 2024-05-13 | 2026-03-27 |
| Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression Ipatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg - Metastatic Breast Cancer, ER+ Breast Cancer | Phase 2 | Active not recruiting | Royal Marsden NHS Foundation Trust | 57 | 2022-12-28 | 2026-04-14 |
| JAB-2485 Activity in Adult Patients With Advanced Solid Tumors JAB-2485 (Aurora A inhibitor) - Solid Tumors, ER+ Breast Cancer | Phase 1 / Phase 2 | Recruiting | Jacobio Pharmaceuticals Co., Ltd. | 102 | 2022-12-20 | 2026-01-09 |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Stereotactic body radiotherapy - Oligometastatic Breast Carcinoma, Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 46 | 2022-09-06 | 2026-10-02 |
| A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen - ER+ Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | Royal Marsden NHS Foundation Trust | 1100 | 2022-03-30 | 2024-12-05 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Entrectinib, Letrozole, Goserelin - Invasive Lobular Breast Carcinoma, ER+ Breast Cancer | Phase 2 | Unknown | Jules Bordet Institute | 65 | 2021-01-14 | 2024-12-04 |
| 4FMFES-PET Imaging of ER+ Advanced Breast Cancers 4FMFES-PET - ER+ Breast Cancer | Phase 2 | Recruiting | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 150 | 2020-11-01 | 2026-07-10 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Seviteronel - Cancer of the Breast, Breast Cancer | Phase 1 / Phase 2 | Completed | Innocrin Pharmaceutical | 175 | 2015-08-01 | 2019-02-01 |
| Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients AZD4547, Exemestane, Placebo - FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer | Phase 1 / Phase 2 | Completed | AstraZeneca | 127 | 2010-12-01 | 2016-02-11 |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing Entinostat, Aromatase Inhibitor (AI) Therapy - ER+ Breast Cancer | Phase 2 | Completed | Syndax Pharmaceuticals | 27 | 2008-10-01 | 2022-06-30 |
| Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer entinostat, exemestane, Placebo - Breast Cancer, Estrogen Receptor-Positive Breast Cancer | Phase 2 | Completed | Syndax Pharmaceuticals | 130 | 2008-06-13 | 2022-05-11 |
Breast Neoplasms (10) · Carcinoma, Lobular (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Mammary Neoplasms, Animal (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Breast Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Breast Neoplasms (2) · Neoplasms, Ductal, Lobular, and Medullary (2) · Adnexal Diseases (1) · Animal Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Fulvestrant (3) · exemestane (3) · palbociclib (3) · Letrozole (2) · abemaciclib (2) · entinostat (2) · ribociclib (2) · AZD4547 (1) · Anastrozole (1) · Aromatase Inhibitors (1) · Everolimus (1) · Goserelin (1) · Radiosurgery (1) · Tablets (1) · Tamoxifen (1)
Memorial Sloan Kettering Cancer Center (2) · Royal Marsden NHS Foundation Trust (2) · Syndax Pharmaceuticals (2) · 858 Therapeutics, Inc. (1) · AstraZeneca (1) · Centre de recherche du Centre hospitalier universitaire de Sherbrooke (1) · Forward Pharmaceuticals Co., Ltd. (1) · Innocrin Pharmaceutical (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Jules Bordet Institute (1) · RayzeBio, Inc. (1) · Yale University (1)
United States (8) · United Kingdom (4) · Canada (3) · France (3) · Belgium (2) · China (2) · Czechia (2) · Hungary (2) · Germany (1) · Ireland (1) · Italy (1) · Romania (1) · Russia (1) · South Korea (1)
Alicia Okines (1) · Amy Xu, MD, PhD (1) · Daniel McCormick (1) · Denise Yardley, MD (1) · Donal Landers (1) · Eric E Turcotte, MD (1) · Mariya Rozenblit, MD (1) · Nicholas Turner (1) · Petrus de Jong, MD, PhD (1) · Philippe Aftimos, MD (1) · Victoria Brown, BS (1)
PMID 23650416, PMID 35119530, PMID 35695563
2009 (1)